Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E25.89 EPS (ttm)1.37 Insider Own0.03% Shs Outstand6.02B Perf Week3.58%
Market Cap213.92B Forward P/E12.90 EPS next Y2.76 Insider Trans-19.44% Shs Float5.92B Perf Month7.89%
Income8.35B PEG4.57 EPS next Q0.64 Inst Own71.30% Short Float0.76% Perf Quarter7.01%
Sales52.35B P/S4.09 EPS this Y5.20% Inst Trans-0.97% Short Ratio2.58 Perf Half Y3.40%
Book/sh9.79 P/B3.63 EPS next Y7.53% ROA4.90% Target Price37.55 Perf Year4.74%
Cash/sh2.38 P/C14.92 EPS next 5Y5.66% ROE14.00% 52W Range29.83 - 35.84 Perf YTD9.45%
Dividend1.28 P/FCF14.07 EPS past 5Y3.30% ROI7.80% 52W High-0.81% Beta0.97
Dividend %3.60% Quick Ratio1.10 Sales past 5Y-2.80% Gross Margin78.20% 52W Low19.18% ATR0.46
Employees96500 Current Ratio1.30 Sales Q/Q-1.90% Oper. Margin20.80% RSI (14)70.60 Volatility2.02% 1.29%
OptionableYes Debt/Eq0.75 EPS Q/Q52.90% Profit Margin16.00% Rel Volume0.96 Prev Close35.55
ShortableYes LT Debt/Eq0.59 EarningsAug 01 BMO Payout88.90% Avg Volume17.48M Price35.55
Recom2.50 SMA204.35% SMA505.86% SMA2007.01% Volume0 Change0.00%
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Sep-19-17 07:34AM  3 Stocks to Buy with Dividend Yields Above 3% Motley Fool
03:30AM  3 High-Yield Pharmaceutical Stocks Motley Fool
Sep-18-17 02:19PM  What Analysts Recommend for Novartis in September 2017 Market Realist
10:30AM  3 High-Yield Healthcare Stocks Motley Fool
10:19AM  Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear InvestorPlace
10:00AM  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
Sep-17-17 07:03AM  Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb Motley Fool
Sep-16-17 03:25PM  3 Stocks to Buy and Hold for Decades Motley Fool
Sep-15-17 10:55AM  Oncology Space in Focus this Week on ESMO Presentations Zacks
10:36AM  Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study Zacks
08:15AM  Pfizer Punches Back at Johnson & Johnson in Prostate Cancer Motley Fool
08:02AM  Dow Jones Closes at New High
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
Sep-14-17 04:11PM  Markets Right Now: Dow ekes out another high in mixed day Associated Press
04:05PM  How This Dow Component Could Double Its Prostate-Cancer Market Investor's Business Daily
04:05PM  Dow Posts Fresh Record, Third in a Row, but S&P 500 and Nasdaq Fall
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
03:06PM  Boeing, United Tech Lead Dow to Records but Rest of Market Flounders
12:20PM  US stocks are mixed as energy companies rise, retailers dip Associated Press
11:51AM  Why Did Pfizer (PFE) Stock Pop Today? Zacks
11:29AM  Pfizer, Astellas prostate cancer drug promising in late-stage trial Reuters
10:18AM  Pfizer Announces Positive Late Stage Trial of Cancer Treatment
10:18AM  Dow Hits Intraday Record but Rest of Market Falters After Inflation Reading
09:51AM  UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial Reuters
09:21AM  The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk Zacks
08:16AM  Pfizer shares rise 1.4% after news of positive late-stage cancer trial MarketWatch
07:40AM  US STOCKS-Futures flat ahead of key inflation data Reuters
07:32AM  Here's Why the Best Is Yet to Come for Opko Health Inc. Motley Fool
05:54AM  Pfizer, Astellas prostate cancer drug clears late-stage trial Reuters
05:00AM  Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer Business Wire
Sep-13-17 05:23PM  Top Analyst Reports for Apple, Pfizer & Carnival Zacks
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:59AM  US Market Indexes Reach New Highs on Tuesday
07:41AM  Teva Pharmaceutical on the Street: Analysts Recommendations in September Market Realist
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
01:11PM  Teva Pharma showing strong gains, IQ100 up 22% CNBC Videos
11:13AM  Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock InvestorPlace
10:25AM  Is There Now An Opportunity In Pfizer Inc (PFE)? Simply Wall St.
10:15AM  Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable Zacks
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
Sep-11-17 11:16AM  AbbVie says deaths in arthritis trial not linked to drug Reuters
10:05AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
09:55AM  FDA's Letter To Pfizer Won't Hurt EpiPen Market
07:40AM  Featured Company News - Pfizer Receives Warning Letter from FDA Highlighting Manufacturing Defects in the EpiPen Administered for Anaphylaxis ACCESSWIRE
07:17AM  Allergan's Patent Loophole Could Be a Huge Gift for Pfizer Motley Fool
07:00AM  Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer Business Wire
Sep-10-17 04:19AM  Lilly takes on Pfizer, Novartis with new breast cancer drug data Reuters
03:15AM  Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress Business Wire
Sep-09-17 06:05PM  Lilly Breast Cancer Drug Results May Challenge Pfizer Pill Bloomberg
Sep-08-17 01:17PM  Feds want to deny Martin Shkreli bail Yahoo Finance Video
11:35AM  Pfizer Accused of Not Investigating EpiPen Failures InvestorPlace
09:23AM  Stocks to Watch: Equifax, Pfizer, Kroger, Southwest, Kura Oncology, American Outdoor Brands The Wall Street Journal
07:49AM  [$$] Pfizer CEO, CFO Sell $13 Million in Stock
07:38AM  Understanding Mercks Valuation after 2Q17 Market Realist
06:53AM  FDA warns of serious manufacturing violations in letter to EpiPen manufacturing facility MarketWatch
06:32AM  Pfizers Meridian Hit With FDA Warning Over EpiPen Flaws Fortune
01:05AM  [$$] FDA Warns Pfizers Meridian Unit on EpiPen Oversight, Quality Issues The Wall Street Journal
12:15AM  PRESS DIGEST- New York Times business news - Sept 8 Reuters
Sep-07-17 11:58PM  PRESS DIGEST - Wall Street Journal - Sept 8 Reuters
07:15PM  [$$] FDA Warns Pfizer's Meridian Unit on EpiPen Oversight, Quality Issues The Wall Street Journal
05:20PM  U.S. FDA warns of problems with EpiPen manufacturing plant Reuters
03:32PM  FDA says there have been 'hundreds of complaints' about EpiPen misfires, some patient deaths followed CNBC
03:23PM  EpiPen Maker Neglected Hundreds of Complaints About Defects Bloomberg
02:11PM  FDA warns of serious manufacturing violations in letter to EpiPen manufacturing facility MarketWatch
11:43AM  3 Alternative Mutual Funds to Ride Out a Spooky September Zacks
08:04AM  3 Top Stocks for Retirees Motley Fool
Sep-06-17 10:05AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
Sep-04-17 09:54AM  Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA Zacks
09:06AM  What to Expect from Pfizers Biosimilars Business Market Realist
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:36AM  An Update on Pfizers Legacy Established Products after 2Q17 Market Realist
Sep-01-17 09:15PM  Pfizer Inc (PFE) Chairman & CEO Ian C Read Sold $6.7 million of Shares
07:09PM  Cramer's biggest investing mistakes CNBC Videos
06:44PM  Cramer admits his biggest investing mistakes CNBC
04:34PM  FDA Approves Pfizer's Leukemia Drug The Wall Street Journal
04:30PM  Pfizer Inc. : PFE-US: Dividend Analysis : August 04th, 2017 (record date) : By the numbers : September 1, 2017 Capital Cube
03:21PM  FDA approves Pfizer's leukemia drug Reuters
03:06PM  FDA approves Pfizer's leukemia drug Reuters
02:41PM  Better Buy: Eli Lilly and Company vs. Pfizer Inc. Motley Fool
02:40PM  3 Stocks That Pay You Motley Fool
11:53AM  FDA approves Pfizer's leukemia drug Reuters
11:38AM  Pfizer Receives FDA Approval for MYLOTARG (gemtuzumab ozogamicin) Business Wire
10:36AM  How Pfizers Enbrel and Xeljanz Are Positioned after 2Q17 Market Realist
09:06AM  Pfizers Sterile Injection Pharmaceuticals in 2Q17 and 1H17 Market Realist
07:36AM  A Post-2Q17 Look at Pfizers Internal Medicines Market Realist
04:18AM  Why Is Pfizer (PFE) Up 2.5% Since the Last Earnings Report? Zacks
Aug-31-17 08:11PM  Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices
12:34PM  Changes in GlaxoSmithKlines Valuation after 2Q17 Market Realist
10:36AM  A Post-2Q17 Update on Pfizers Oncology Drugs: Sutent, Xalkori, and Inlyta Market Realist
09:26AM  The Medicines Company's Infection Drug Vabomere Gets FDA Nod Zacks
09:06AM  How Pfizers Rare Disease Franchise Stands after 2Q17 Market Realist
08:54AM  Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease Business Wire
08:05AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:37AM  How Pfizers Prevnar 13 and Lyrica Stand after 2Q17 Market Realist
Aug-30-17 11:46AM  Merck: Heartbreak Over A Cholesterol Drug
10:37AM  Pfizers Ibrance Could See Robust Growth in 2H17 Market Realist
10:01AM  Gilead-Kite: A New Transformative Deal For Biotech Forbes
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; collaboration with Merck and Corning for pharma glass packaging project; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUSMAN SALLYExecutive Vice PresidentSep 12Sale35.0038,2301,338,050115,096Sep 14 09:13 AM
MACKENZIE ALEXANDER RExecutive Vice PresidentSep 01Sale34.007,350249,900124,774Sep 05 06:15 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 31Sale34.007,350249,900132,124Sep 01 06:37 PM
DAMELIO FRANK AExecutive Vice PresidentAug 31Sale34.0094,4093,209,906337,389Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.00141,1934,800,56280,762Sep 01 06:37 PM
READ IAN CChairman & CEOAug 31Sale34.0055,9751,903,150580,318Sep 01 06:37 PM
OLSON LAURIE JExecutive Vice PresidentAug 21Sale32.708,064263,69374,506Aug 23 03:51 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 07Sale33.5015,000502,560139,474Aug 09 05:00 PM
READ IAN CChairman & CEOAug 04Sale34.0068,8342,340,356221,955Aug 08 05:02 PM
READ IAN CChairman & CEOAug 04Sale34.0028,116955,944636,293Aug 08 05:02 PM
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM